1. Patient induced pluripotent stem cell-derived hepatostellate organoids establish a basis for liver pathologies in telomeropathies
- Author
-
Christopher J. Lengner, Corbett T. Berry, Joshua H. Rhoades, Stephanie Adams-Tzivelekidis, Zvi Cramer, F. Brad Johnson, Qijun Chen, Youngjun Choi, Nicolette M. Johnson, Melissa S. Kim, Sarah Root, Rafael Fernandez, Yuhua Tian, and Ning Li
- Subjects
Cirrhosis ,medicine ,Organoid ,Hepatic stellate cell ,Cancer research ,CRISPR ,Hyperplasia ,Biology ,medicine.disease ,Induced pluripotent stem cell ,Phenotype ,Dyskeratosis congenita - Abstract
Patients with dyskeratosis congenita (DC) and related telomeropathies resulting from premature telomere dysfunction suffer from multi-organ failure. In the liver, DC patients present with nodular hyperplasia, steatosis, inflammation, and cirrhosis. We model DC liver pathologies using isogenic human induced pluripotent stem (iPS) cells harboring a causal DC mutation in DKC1, or a clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-corrected control allele. Differentiation of these iPS cells into hepatocytes or hepatic stellate cells followed by generation of genotype-admixed hepatostellate organoids revealed a dominant phenotype in the parenchyma, with DC hepatocytes eliciting a pathogenic hyperplastic response in stellate cells independent of stellate cell genotype. Pathogenic phenotypes could be rescued via suppression of AKT activity, a central regulator of MYC-driven hyperplasia downstream of DKC1 mutation. Thus, isogenic iPS-derived admixed hepatostellate organoids offer insight into the liver pathologies in telomeropathies and provide a framework for evaluating emerging therapies.
- Published
- 2021
- Full Text
- View/download PDF